Matching articles for "prediabetes"
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Metformin for Prediabetes
The Medical Letter on Drugs and Therapeutics • November 7, 2016; (Issue 1507)
The oral biguanide metformin (Glucophage, and
others) is generally the drug of choice for initial
treatment of type 2 diabetes. It has also been used
to prevent or at least delay the onset of diabetes
in...
The oral biguanide metformin (Glucophage, and
others) is generally the drug of choice for initial
treatment of type 2 diabetes. It has also been used
to prevent or at least delay the onset of diabetes
in patients considered to be at high risk for the
disease. Recent guidelines recommend considering
use of metformin in patients with prediabetes
(fasting plasma glucose 100-125 mg/dL, 2-hr post-load
glucose 140-199 mg/dL, or A1C 5.7-6.4%),
especially in those who are <60 years old, have
a BMI >35 kg/m2, or have a history of gestational
diabetes. Metformin has not been approved for
such use by the FDA.